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We examined prospectively the outcome of primary 
and nonprimary maternal cytomegalovirus (CMV) infection 
during pregnancy among 88 and 120 women, respectively. 
The risk for vertical transmission was 1.83× higher for pri-
mary infection than for nonprimary infection. Nonetheless, 
congenital CMV disease was diagnosed in both infection 
groups at similar rates.
C
ytomegalovirus (CMV) infection is the most frequent 
congenital infection and a common cause of deafness 
and intellectual impairment, affecting 0.5%–2.5% of all 
live births (1–3). Intrauterine infection occurs in 40% of 
primary maternal infections, with delivery of 10% to 15% 
symptomatic newborns and late neurologic sequelae in 
10% of those asymptomatic at birth (1).
Although preexisting maternal immunity reduces ma-
ternal-fetal transmission, the severity of congenital CMV 
disease is similar following primary or nonprimary in-
fection (4–7). Yet, several reports found increased verti-
cal transmission after nonprimary CMV infection (4–9). 
Therefore, our objective was to examine the outcome of 
primary and nonprimary maternal CMV infections during 
pregnancy.
The Study
Institutional Ethics Committee approval was obtained. 
Women with positive CMV immunoglobulin (Ig) M (n = 
208), referred for risk for CMV infection between January 
1998 and December 2001, were enrolled in this prospective 
cohort observational study. Clinical and pregnancy-related 
information was obtained. Serum CMV IgG and IgM were 
measured by enzyme immunoassay and CMV-IgM immu-
noﬂ  uorescence assay (10). IgG avidities <25% indicated 
recent infection (10).
Ultrasonographic examinations were performed be-
tween the 15th and 21st weeks of pregnancy. The reference 
method for prenatal diagnosis of CMV, requiring combined 
viral isolation and positive CMV PCR from amniotic ﬂ  uid 
after gestational week 21 or 7 weeks after maternal symp-
toms (3,11), was applied for all amniocenteses. Amniotic 
ﬂ   uid samples were inoculated onto MRC5 monolayers 
for CMV isolation (10), and DNA was ampliﬁ  ed by PCR 
(10,12). Parents made decisions regarding amniocentesis 
and the fate of pregnancy after medical, and sometimes 
rabbinical, consultations. Elective terminations of pregnan-
cy (ETOP) required external committee approval. Avail-
able aborted fetuses were examined for CMV-induced 
histopathologic changes. Immediately after birth, neonatal 
urine and anti–CMV IgM were examined. Subsequently, 
the newborns underwent cerebral ultrasound and auditory 
and ophthalmologic assessment.
Primary infection was deﬁ  ned as the occurrence of 
anti–CMV IgG seroconversion during pregnancy (1). 
Women who were seropositive for anti–CMV IgM and 
anti–CMV IgG when ﬁ  rst evaluated during pregnancy and 
with IgG avidity >35% were considered to have nonpri-
mary infection (12). The latter were divided into those with 
preconception evidence of anti–CMV IgG and negative 
anti–CMV IgM (group 1) and those without prior tests for 
CMV (group 2). Vertical transmission was declared if the 
amniotic ﬂ  uid contained CMV virus or DNA, if pathologic 
features of CMV disease existed in the aborted fetus, or if 
neonatal IgM or urine cultures were positive for CMV.
Analysis of variance and the Kruskal-Wallis or Mann-
Whitney tests were used. Frequencies were compared by χ2 
or Fisher exact tests. Relative risk was calculated with Epi 
Info 2000 software (available from www.cdc.gov/epiinfo).
Of the 208 enrolled women, 88 (42.3%) had primary 
CMV infection; 120 (57.7%) had nonprimary CMV in-
fection, 36 (17.3%) from group 1 and 84 (40.4%) from 
group 2. The mothers’ ages were similar in both groups. 
The median gestational age upon referral was 15 weeks 
(9.5–19.0 weeks), and the median number of pregnancies 
was 3 (range 1–10). CMV serologic testing was part of 
the routine gynecologic examination in 127 (61.0%) of the 
women: 35 (39.8%) after primary infection and 92 (76.6%) 
in the nonprimary infection group (p<0.001). Clinical signs 
of CMV infection triggered 52 (25%) of the tests, while 
patient anxiety induced the rest. Clinical CMV symptoms 
were more common with primary than with nonprimary 
infections (53 [60.2%], and 44 [36.6%], respectively, p = 
0.002).
Pregnancies with primary infection had signiﬁ  cantly 
fewer live births than those with nonprimary infection 
(Table 1). Primary infections in the ﬁ  rst 20 gestational 
weeks resulted in 46.5% live births, 46.5% ETOP, and 7% 
miscarriages, while pregnancies with such infections after 
week 23 were 100% full term (p = 0.004).
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The following analysis included 169 women (exclud-
ing 39 with miscarriages or ETOP before week 21). Of 
them, 100 had amniocentesis, with most in the nonprimary 
infection group 2, 62.7% (52/83), and the rest similarly dis-
tributed between nonprimary group 1, 42.9% (15/35), and 
primary infection, 40.7% (33/81). Approximately half of 
the amniocenteses provided evidence of fetal CMV infec-
tion, both in primary infection (16/33) and nonprimary in-
fection group 1 (7/15), but only in 17.3% (9/52) of group 2 
(p<0.001). Vertical transmission was determined from the 
amniotic ﬂ  uid by culture (n = 12) or PCR (n = 30), abortus 
pathology (n = 6), or positive neonatal IgM (n = 2) or urine 
cultures (n = 13). Vertical transmission rates were 35.8% 
(24/76), 30.0% (9/30), and 15.3% (11/72) in the primary 
and nonprimary infection groups 1 and 2, respectively (p = 
0.017). The relative risk for vertical transmission in prima-
ry infection was 1.83 (95% conﬁ  dence interval 1.1–3.03, p 
= 0.019) versus nonprimary infection.
All liveborn babies had similar natal characteristics 
regardless of the maternal infection group. Four newborns 
and 7 aborted fetuses (6.5%, 11/169) had congenital CMV 
disease (Table 2), 6.0% (4/67) after primary CMV infection 
and 6.9% (7/102) after nonprimary infection, with 13.3% 
(4/30) in group 1 and 4.2% (3/72) in group 2 (p = 0.26). 
Three of the 4 mentally retarded neonates were born af-
ter nonprimary infection. CMV infection was not detected 
in newborns of mothers with negative prenatal diagnostic 
tests (n = 68).
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Table 1. Outcome of pregnancies by type of CMV infection* 
Outcome of pregnancy  Primary infection (%)  Nonprimary infection (%)  Total p value 
Live birth  51 (58.0)  97 (80.8)  148 <0.001
ETOP* 30 (34.0)  21 (17.5)  51 0.006
Miscarriage† 7 (8.0)  2 (1.7)  9 0.038
Total 88 120 208
*CMV, cytomegalovirus; ETOP, elective termination of pregnancy. Thirty ETOP were performed during the first trimester, 21 between the 21st and 23rd 
weeks of pregnancy. 
†Mean gestational age of miscarried fetuses was 7 wk. 
Table 2. Characteristics of aborted fetuses and neonates with congenital CMV disease* 
Case no. 
Maternal
infection
Maternal
symptoms 
Week of 
infection US AF Outcome, wk 
Natal/abortion
status Follow-up, 2 y 
1 Primary Flu <20 IUGR
microcephaly 
+ Live born, 38  Congenital
disease
Sensorineural
hearing loss, 
PMR
2 Primary None <18 Hyperechoic 
bowel 
ND Abortion, 19  Postmortem:
disseminated
CMV
3 Primary Fever 7 Hyperechoic 
bowel 
+ Abortion, 23  Postmortem:
disseminated
CMV
4 Primary Fever 12 None + Abortion, 24 Postmortem:
disseminated
CMV
5 Nonprimary 
(group 1) 
None Unclear IUGR ND Live born, 38  Brain
calcifications 
PMR
6 Nonprimary 
(group 1) 
Flu 22 Tricuspid
regurgitation
ND Abortion, 33  Postmortem:
disseminated
CMV
7 Nonprimary 
(group 1) 
Fever 20 IUGR
pericardial
fluid, brain 
calcifications 
+ Abortion, 30  Postmortem:
disseminated
CMV
8 Nonprimary 
(group 1) 
Flu <20 None + Live born, 40  Congenital
disease
PMR
9 Nonprimary 
(group 2) 
Fever 12 ND + Abortion, 24  Postmortem:
disseminated
CMV
10 Nonprimary 
(group 2) 
Flu 4 ND ND Live born, 38  Congenital
disease
Sensorineural
hearing loss, 
PMR
11 Nonprimary 
(group 2) 
None 14 Liver
calcifications 
+ Abortion, 24  Postmortem:
disseminated
CMV
*CMV, cytomegalovirus; US, ultrasonography; AF, amniotic fluid; IUGR, intrauterine growth retardation; +, positive according to PCR, culture, or both; ND, 
not done; PMR, psychomotor retardation. CMV Infection during Pregnancy
Conclusions
To our knowledge, this is the ﬁ  rst cohort in which the 
natural history of nonprimary CMV infection was evalu-
ated prospectively in the mother from pregnancy to its 
conclusion, in contrast to published studies that determined 
it from established neonatal infection and retrospective as-
sessment of the mothers’ serologic test results (2,4–8,13). 
Most  Israeli physicians obtain CMV serologic test results 
in pregnancy in response to women’s demands and as a 
precaution, but the results, mainly of nonprimary infection, 
are confusing. Our ﬁ  ndings suggest that nonprimary infec-
tion is also dangerous. While vertical transmission after 
primary CMV infection was similar to the reported 30% 
to 40% (1,3,11), after nonprimary infection it was 19.6%, 
much higher than the published 2.2% (1–3,13). Further-
more, of the 11 cases of congenital CMV disease, 7 were 
associated with nonprimary maternal infection. 
The high rate of vertical transmission in the nonpri-
mary infection group attests to the numerous amniocen-
teses performed in Israel to exclude fetal infection. The 
procedure is considered safe because neonatal loss rates in 
those undergoing it and not undergoing it are identical (14), 
and the risks of undergoing the procedure do not outweigh 
the risks for congenital CMV infection. In the nonprimary 
group, 67 (55.8%) had amniocentesis, but in the primary 
infection group, only 33 (37.5%) underwent the procedure, 
which reﬂ  ects the increased early ETOP rate with primary 
infection.
Traditionally, vertical transmission after nonprimary 
infection was established by isolating CMV from neona-
tal saliva or urine, or the presence of neonatal IgM (4–8). 
We, however, determined transmission also from CMV in 
the amniotic ﬂ  uid, and the observed difference between 
amniotic CMV and neonatal CMV disease suggests fetal 
virus elimination between amniocentesis and birth, prob-
ably by preexisting maternal CMV-speciﬁ  c antibodies. The 
high transmission rate could have resulted also from rein-
fection by CMV strains different from the primary strain 
(6), further enhanced by increased virulence of present-day 
strains. 
The high proportion (>40%) of religiously observant 
women accounts for the reluctance of some to terminate 
pregnancy without ultrasonographic and amniocentesis 
evidence of fetal infection and also for the increased early 
ETOP (permitted by Jewish law only before the second 
trimester). We are aware that data were obtained for only 
169/199 (84.9%) of fetuses or newborns and that only 31/51 
(60.8%) of the aborted fetuses were available for examina-
tion, but omissions were random. Possible referral selec-
tion bias and the low number of affected women discour-
age deﬁ  nitive conclusions. Nevertheless, both primary and 
nonprimary CMV infection during pregnancy are clearly 
important causes of congenital disease.
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